Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:03:50.477Z.
Calculation as of: 2026-10-06T17:03:50.477Z.
Quote observation: 2026-10-06T17:00:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Prelude Therapeutics Incorporated
Market Cap
$213.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.44M
Operating Cash Flow Yield
2.79%
TTM Avg
2.54%
3Y Avg
2.69%
5Y Avg
2.62%
Market Cap
$211.48M
Operating Cash Flow Yield
N/A
TTM Avg
41.63%
3Y Avg
41.53%
5Y Avg
35.39%
Market Cap
$216.34M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.05M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.98M
Operating Cash Flow Yield
N/A
TTM Avg
10.33%
3Y Avg
10.33%
5Y Avg
10.33%
Market Cap
$206.61M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.06M
Operating Cash Flow Yield
3.51%
TTM Avg
3.82%
3Y Avg
6.32%
5Y Avg
5.85%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $213.21M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $213.44M | 2.79% | 2.54% | 2.69% | 2.62% |
| Alector, Inc. (ALEC)vs › | $211.48M | N/A | 41.63% | 41.53% | 35.39% |
| Compugen Ltd. (CGEN)vs › | $211.33M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.34M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $209.05M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.98M | N/A | 10.33% | 10.33% | 10.33% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $206.06M | 3.51% | 3.82% | 6.32% | 5.85% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $220.74M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
